SCHEMBL31165289

SCHEMBL31165289

C=Cc1ccc(Cn2c3ccccc3c3cc(Br)ccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ CYP19A1 P11511 1/20 0.49
▸ DNM1 Q05193 2/20 0.48
▸ MEN1 O00255 1/20 0.45
▸ RAD52 P43351 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TSPO P30536 2/20 0.44
▸ HDAC6 Q9UBN7 3/20 0.44
▸ HDAC1 Q13547 2/20 0.44
▸ HDAC10 Q969S8 2/20 0.44
▸ KRAS P01116 2/20 0.43
▸ P2RX4 Q99571 2/20 0.41
▸ NPM1 P06748 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC7 Q8WUI4 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16627135 1.00 PSMD14 (0.51) PSMD14LMNATP53MAPTCYP19A1
SCHEMBL28337505 0.92 LMNA (0.51) PSMD14LMNATP53MAPTCYP19A1
SCHEMBL30681661 0.87 CYP19A1 (0.63) PSMD14LMNACYP19A1MEN1KMT2A
SCHEMBL955942 0.87 CYP19A1 (0.63) PSMD14LMNACYP19A1MEN1KMT2A
SCHEMBL29405472 0.87 CYP19A1 (0.63) PSMD14LMNACYP19A1MEN1KMT2A
SCHEMBL17457937 0.86 PSMD14 (0.53) PSMD14LMNATP53MAPTCYP19A1
SCHEMBL2246814 0.84 CYP19A1 (0.70) TP53MAPTCYP19A1DNM1MEN1
SCHEMBL25841829 0.83 CYP19A1 (0.64) PSMD14LMNAMAPTCYP19A1MEN1
SCHEMBL10064304 0.83 PSMD14 (0.50) PSMD14LMNATP53MAPTCYP19A1
SCHEMBL8173916 0.82 CYP19A1 (0.57) TP53MAPTCYP19A1DNM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof KAUNAS UNIVERSITY OF TECHNOLOGY (LT) 2024-10-17 — — US disclosed
EP-4447643-A1 IN-SITU CROSSLINKING OF 9,9`-SPIROBIFLUORENE-BASED COMPOUNDS FOR USE IN OPTOELECTRONIC AND/OR PHOTOELECTROCHEMICAL DEVICES AND MANUFACTURE THEREOF Kaunas University of Technology (LT) 2024-10-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof INTS9, SLC6A9, SLC19A1 PSMD14 1193/4885LMNA 1181/4885TP53 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback